|[August 13, 2014]
Exactech Announces First Implantation of New Alteon™ Tapered Wedge Femoral Stem
GAINESVILLE, Fla. --(Business Wire)--
Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products for hip, knee, shoulder, spine and biologic
materials, is proud to announce the first implantation of the Alteon™
Tapered Wedge Femoral Stem. The surgery took place at Franciscan St.
Francis Health in Carmel, Ind., and was performed by orthopaedic surgeon
Jeffery Pierson, MD, a member of the design team for this new hip
"It has been an incredibly gratifying experience to be directly involved
in the design and development of a device that performed as well in
surgery as I anticipated it would," said Pierson. "Clinically relevant
improvements to devices, such as the ones we made with the new Tapered
Wedge Stem, allow us to continue to provide the best standard of care to
Over the past two years, Dr. Pierson and Michael Kang, MD, from the
Insall-Scott-Kelly Institute in New York, N.Y., consulted with Exactech
to bring to market a newly designed stem that addresses several clinical
challenges that many surgeons face with current product design
The Tapered Wedge Stem, which is currently in the pilot launch phase of
release, incorporates specific features designed to achieve axial and
rotational mechanical stability between the lateral and medial cortices
of the femoral canal. This product will be expanding to a limited number
of additional sites within the coming months, and company officials
report a full launch within the U.S. is expected to take place in
January of 2015.
"We are pleased to provide this technology to patients who can benefit
from the Alteon Tapered Wedge Stem," said Exactech CEO David Petty.
"This design philosophy represents about 40 percent of the market for
cemetless stems in the U.S. This new products gives us an opportunity
to reach many more patients needing total hip replacement."
Based in Gainesville, Fla., Exactech develops and markets orthopaedic
implant devices, related surgical instruments and biologic materials and
services to hospitals and physicians. The company manufactures many of
its orthopaedic devices at its Gainesville facility. Exactech's
orthopaedic products are used in the restoration of bones and joints
that have deteriorated as a result of injury or diseases such as
arthritis. Exactech markets its products in the United States, in
addition to more than 30 markets in Europe, Latin America, Asia and the
Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com.
Copies of Exactech's press releases, SEC (News - Alert) filings, current price quotes
and other valuable information for investors may be found at http://www.exac.com
An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm.
To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934, which represent the company's
expectations or beliefs concerning future events of the company's
financial performance. These forward-looking statements are further
qualified by important factors that could cause actual results to differ
materially from those in the forward-looking statements. These factors
include the effect of competitive pricing, the company's dependence on
the ability of third party manufacturers to produce components on a
basis which is cost-effective to the company, market acceptance of the
company's products and the effects of government regulation. Results
actually achieved may differ materially from expected results included
in these statements.
[ Back To TMCnet.com's Homepage ]